“But also our international launches, our launch in Japan has gone extremely well... TEPEZZA will be a a good growth driver for us this year.”

In context

“ep. Thanks, Jay. As Jay mentioned, we're expanding our treatment for patients with thyroid eye disease into the lower clinical activity score patient population who tends to be managed by different specialists than the higher clinical activity score patients. We have historically been able to drive very strong penetration with oculoplastic surgeons and general ophthalmologists we are expanding our prescribing base to include endocrinologists. We made investments at the beginning of last year and those investments are starting to return now by an increased base of endocrinologists prescribing So that's in The U.S. And we expect that we'll continue to broaden our treatment of the low clinical activity score patients while maintaining our share of the higher clinical activity score patients. But also our international launches, our launch in Japan has gone extremely well. We're seeing nice uptake there. We're seeing a very well-received product for higher clinical activities for patients, and we're in the process of launching in multiple markets around the world as we speak. So overall, TEPEZZA will be a a good growth driver for us this year. Thank you. Let's go to the next question. Julianne: Thank you, Louise. Our next question comes from Terence Flynn from Morgan Stanley. Please Terence Flynn: Hi, thanks for taking the question. I had one on the Miratide Phase III program. Appreciate all the details today, but just was wondering if you have any update in terms of how to think about the design of the Type II diabetes CVOT trial, particularly the control arm as I know that's something that you guys were debating here post the, you know, seeing some of the data from some of the competitors but just wondering how y”